Salinomycin-sodium-salt-Salinomycin-sodium-DataSheet-生命科学试剂-MedChemExpress_第1页
Salinomycin-sodium-salt-Salinomycin-sodium-DataSheet-生命科学试剂-MedChemExpress_第2页
Salinomycin-sodium-salt-Salinomycin-sodium-DataSheet-生命科学试剂-MedChemExpress_第3页
Salinomycin-sodium-salt-Salinomycin-sodium-DataSheet-生命科学试剂-MedChemExpress_第4页
全文预览已结束

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESalinomycin sodium saltCat. No.: HY-17439CAS No.: 55721-31-8Synonyms: Salinomycin sodium; Sodium salinomycin分式: CHNaO分量: 772.98作靶点: Bacterial作通路: Anti-infection储存式: 4C, stored under nitrogen* In solvent : -80C, 6 months; -20C, 1

2、 month (stored undernitrogen)溶解性数据体外实验 DMSO : 15 mg/mL (19.41 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.2937 mL 6.4685 mL 12.9369 mL5 mM 0.2587 mL 1.2937 mL 2.5874 mL10 mM 0.1294 mL 0.6468 mL 1.2937 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。B

3、IOLOGICAL ACTIVITY物活性 Salinomycin sodium salt具有强的抗 (anti-bacterial) 活性的抗球药,和靶向类癌症细胞的新型抗癌剂。IC50 & Target bacterial 1体外研究Salinomycin (0.1-8 M) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and1/3 Master of Small Molecules 您边的抑制剂师www.MedChemE59.2% inhibition at 4 and 8 M

4、, respectively. HUVECs exposed to 2, 4 and 8 M of Salinomycin for 48 hshow a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 M)treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tubeformation of HUVECs. Sa

5、linomycin significantly suppresses the expression levels of phosphorylated (p)-FAKin a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbingthe VEGF-VEGFR2-AKT signaling axis 1. Combination of RSVL and Salinomycin synergistically inhibits theproliferation o

6、f TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colonyand tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycininduces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2expression as

7、comparison to untreated and alone drug treatments 2. Salinomycin (0, 2, 4, 8 and 16 M)significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner,(IC50 24h: 13.8 M, IC50 48h: 6.888 M and IC50 72h: 4.382 M for A2780 cell lines), (IC50 24h: 12.7 M,IC50

8、 48h: 9.869 M and IC50 72h: 5.022 M for SK-OV-3 cell lines). Salinomycin blocks the Wnt/-cateninpathway in EOC cells 3. Salinomycin (2 M) reduces cancer cell proliferation, inhibits STAT3phosphorylation and P38 and -catenin expressions, and suppresses epithelial-mesenchymal transition incolorectal c

9、ancer cells. Salinomycin (1-5 M) inhibits cancer cell proliferation and STAT3 signaling incolorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomeraseactivity whe

10、n combined with telomerase inhibitor 4.体内研究 Salinomycin (5 and 10 mg/kg) significantly supresses the average tumor volume and tumor weight.Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis withinvolvement of AKT and FAK dephosphorylation 1. Salinomycin (0.5

11、 mg/kg b.wt.) enhances the meansurvival time of the tumor bearing Swiss albino mice 2.PROTOCOLCell Assay 1 The effect of Salinomycin on HUVEC growth is determined by MTT assay. Briefly, HUVECs (6,000 cells/well)are seeded in 96-well culture plates for 24 h and incubated with different concentrations

12、 of Salinomycin. Inthe preliminary experiments, Salinomycin treatment for 12, 24, 48 and 72 h shows time-dependent effects oncell growth inhibition. However, treatment for 48 h is the optimal time and is selected for further mechanismevaluation. After Salinomycin treatment for 48 h, 20 L/well of MTT

13、 solution (5 mg/mL) is added andincubated for 5 h. The medium is aspirated and replaced with 200 L/well of DMSO to dissolve the formazanSalinomycint formed. The color intensity of the formazan solution is measured at 570 nm by a microplatespectrophotometer. The cell viability is expressed as % of th

14、e control (as 100%).MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Human glioma U251 cells (1107) suspended in 100 L PBS are injected into the right lower hind flank ofAdministration 1 each 6-week-old male nude mouse. The mice are then randomly

15、assigned into three groups of 10 mice ineach group. After one week, Salinomycin (5 and 10 mg/kg) is administered into the caudal vein every otherday for 16 days. Control mice receive an equal volume of vehicle (Salinomycinine) only. Body weight andtumor volume are monitored every two days. At the en

16、d of the experiments, tumors are excised,photographed, and weighed. Tumors from each group are used for western blotting and2/3 Master of Small Molecules 您边的抑制剂师www.MedChemEimmunohistochemical (IHC) assay.MCE has not independently confirmed the accuracy of these methods. They are for reference only.

17、户使本产品发表的科研献 Cell Commun Signal. 2018 Nov 23;16(1):89. Int J Mol Sci. 2019 Aug. Int J Mol Sci. 2019 Jun 12;20(12). pii: E2861. Oncol Rep. 2018 Aug;40(2):877-886.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Bi YL, et al. Salinomycin exhibits anti-angiogenic activity against hu

18、man glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. Int J Mol Med. 2017 Mar 292. Rai G, et al. Evaluation of growth inhibitory response of Resveratrol and Salinomycin combinations against triple negative breast cancercells. Biomed Pharmacother. 2017 Mar 11;89:1142-11513. Li R, et al. Salinomycin repressed the epithelial-mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/-catenin pathway. Onco Targets Ther. 2017 Feb 28;10:1317-1324. Chung SS, et al. Salinomycin Abolished STAT3 and STAT1 Interactions and Reduced

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论